← Back
$RXRX All transactions

RECURSION PHARMACEUTICALS, INC.

▼ SELL 10b5-1 Plan

$ Value

$95K

Shares

28,298

Price

$3

Filed

Mar 11

Insider

Name

Khan Najat

Title

CEO and President

CIK

0002020969

Roles

Director Officer

Transaction Details

Transaction Date

2026-03-09

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

2,262,085

Footnotes

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025 | This transaction was executed in multiple trades at prices ranging from $3.32 to $3.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Filing Info

Accession No.

0001601830-26-000048

Form Type

4

Issuer CIK

0001601830

Khan Najat's History

Date Ticker Type Value
2026-03-09 RXRX $95K
2026-02-17 RXRX F $50K
2026-02-06 RXRX A $0
2026-02-06 RXRX A $0
2026-02-06 RXRX F $41K
2025-12-22 RXRX $549K
2025-11-17 RXRX F $73K
2025-11-05 RXRX A $0
2025-11-05 RXRX A $0
2025-08-18 RXRX $202K

Other Insiders at RXRX (90d)

Insider Bought Sold Last
Taylor Ben R
Chief Financial Officer
$68K 2026-04-06
Li Dean Y 2026-04-01
Dar Zavain 2026-04-01
Borgeson Blake $1.6M 2026-04-07
Gibson Christopher $557K 2026-04-07
Hallett David
Chief Scientific Officer
2026-02-17
Khan Najat
CEO and President
2026-02-17